U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06997029) titled 'A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors' on May 21.
Brief Summary: The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Study Start Date: Aug. 15, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Advanced Breast Cancer
Advanced Ovarian Cancer
Intervention:
DRUG: BMS-986500
Specified dose of specified days
DRUG: Palbociclib
Specified dose on specified days
DRUG: Fulvestrant
Specified dose on specified days
Recruitment Status: NOT_YET_RECR...